Adaptimmune Therapeutics And TCR² Therapeutics To Merge (All-Stock)

Treadwell Therapeutics Acquires TCRyption Inc.

October 15, 2021

Biotechnology

Treadwell Therapeutics announced it has acquired TCRyption Inc., a TIO Bioventures–backed developer of a novel TCR-identification platform for T cell therapies, in a stock-swap transaction. The acquisition brings the TCRypt platform and a bank of TCR candidates into Treadwell's pre-clinical oncology pipeline to expand its cell-therapy capabilities, with initial TCR programs expected to enter the clinic in early 2023.

Candid Therapeutics to Merge With Rallybio (Creating Nasdaq-listed Candid Therapeutics)

March 5, 2026

Biotechnology

Clinical-stage biotechnology company Candid Therapeutics signed a merger agreement with Rallybio Corporation to create a combined company focused on developing T cell engager therapies for autoimmune diseases. The transaction is expected to close in mid-2026, pending customary approvals and conditions, and Candid also secured an oversubscribed private financing of more than $505 million led by healthcare institutional investors.

Takeda Acquires Adaptate Biotherapeutics

January 10, 2022

Biotechnology

Takeda Pharmaceutical Company Limited has exercised its option to acquire Adaptate Biotherapeutics, a UK biotechnology spin-out focused on antibody-based γδ T cell engager therapies for solid tumors. The acquisition gives Takeda Adaptate’s antibody-based γδ T cell engager platform and preclinical pipeline to strengthen Takeda’s immuno-oncology capabilities and accelerate development of Vδ1‑targeting therapies.

AbCellera Acquires TetraGenetics

September 13, 2021

Biotechnology

AbCellera Biologics Inc. acquired TetraGenetics, Inc. in an all-cash transaction to integrate TetraGenetics' recombinant transmembrane protein expression platform into AbCellera's antibody discovery technology stack. The acquisition expands AbCellera's ability to generate antibodies against difficult-to-drug ion channels, GPCRs and other transmembrane targets, and includes upfront and milestone-based payments.

Research Corporation Technologies Acquires Translational Drug Development (TD2)

June 4, 2020

Healthcare Services

Research Corporation Technologies, Inc. (RCT) has acquired Translational Drug Development (TD2) and provided growth capital to expand TD2's precision oncology drug development services. The transaction will scale TD2's translational preclinical, regulatory and clinical trial capabilities to better serve biotechnology and pharmaceutical clients.

Taconic Biosciences Acquires TransCure bioServices

January 20, 2026

Biotechnology

Taconic Biosciences has acquired TransCure bioServices SAS to create an integrated global translational research platform combining Taconic's genetically engineered and humanized mouse models with TransCure's preclinical in vivo services. The deal expands Taconic's capabilities across oncology, immunology, infectious disease, and advanced modalities while preserving TransCure's brand and operational structure to ensure continuity for employees and clients.